2022
A translational genomics approach identifies IL10RB as the top candidate gene target for COVID-19 susceptibility
Voloudakis G, Vicari J, Venkatesh S, Hoffman G, Dobrindt K, Zhang W, Beckmann N, Higgins C, Argyriou S, Jiang S, Hoagland D, Gao L, Corvelo A, Cho K, Lee K, Bian J, Lee J, Iyengar S, Luoh S, Akbarian S, Striker R, Assimes T, Schadt E, Lynch J, Merad M, tenOever B, Charney A, Brennand K, Fullard J, Roussos P. A translational genomics approach identifies IL10RB as the top candidate gene target for COVID-19 susceptibility. Npj Genomic Medicine 2022, 7: 52. PMID: 36064543, PMCID: PMC9441828, DOI: 10.1038/s41525-022-00324-x.Peer-Reviewed Original ResearchCandidate gene targetsGene targetsTranslational genomics approachesHost susceptibilityGenomic approachesGenetic susceptibility variantsGenetic lociDruggable genesGene expressionMolecular pathwaysSusceptibility variantsCOVID-19 susceptibilityGenetic findingsApproach identifiesExpressionCOVID-19 patient bloodCritical next stepGenesLociOverexpressionTargetPathwaySusceptibilityIL10RBRecent effortsCOVID-19 susceptibility and clinical outcomes in autoimmune inflammatory rheumatic diseases (AIRDs): a systematic review and meta-analysis.
Shin J, Kim S, Lee M, Kim M, Lee S, Park S, Shin Y, Yang J, Song J, Moon S, Kim S, Park Y, Suh D, Yang J, Cho S, Jin H, Hong S, Won H, Kronbichler A, Koyanagi A, Jacob L, Hwang J, Tizaoui K, Lee K, Kim J, Yon D, Smith L. COVID-19 susceptibility and clinical outcomes in autoimmune inflammatory rheumatic diseases (AIRDs): a systematic review and meta-analysis. European Review For Medical And Pharmacological Sciences 2022, 26: 3760-3770. PMID: 35647859, DOI: 10.26355/eurrev_202205_28873.Peer-Reviewed Original ResearchConceptsAutoimmune inflammatory rheumatic diseasesConventional synthetic disease-modifying antirheumatic drugsClinical outcomes of COVID-19Outcomes of COVID-19Clinical outcomesInflammatory rheumatic diseasesAIRD patientsMeta-analysisSynthetic disease-modifying antirheumatic drugsRheumatic diseasesDisease-modifying antirheumatic drugsSusceptibility to COVID-19Case-control studySevere outcomes of COVID-19Increased susceptibility to COVID-19Antirheumatic drugsRelated deathsPatientsSteroidsDrug useGeneral populationCOVID-19 susceptibilitySystematic reviewNO effectCOVID-19Susceptibility of Patients with Inflammatory Bowel Disease to COVID-19 Compared with Their Households
Anushiravani A, Saberzadeh-Ardestani B, Vahedi H, Fakheri H, Mansour-Ghanaei F, Maleki I, Nasseri-Moghaddam S, Vosoghinia H, Ghadir M, Hormati A, Kasaeian A, Radmard A, Khosravi B, Malekzadeh M, Alatab S, Sadeghi A, Aminisani N, Poustchi H, Sima A, Malekzadeh R. Susceptibility of Patients with Inflammatory Bowel Disease to COVID-19 Compared with Their Households. Middle East Journal Of Digestive Diseases 2022, 14: 182-191. PMID: 36619152, PMCID: PMC9489316, DOI: 10.34172/mejdd.2022.271.Peer-Reviewed Original ResearchInflammatory bowel diseaseAnti-TNF monotherapySevere inflammatory bowel diseasePrevalence of COVID-19Susceptibility of patientsSeverity of inflammatory bowel diseaseTreatment of inflammatory bowel diseaseData of patientsMultivariate logistic regressionFrequency of COVID-19Immunosuppressive agentsRisk of coronavirus disease 2019Associated with COVID-19Multivariate analysisMulti-centerBowel diseasePatientsRisk factorsObservational studyCoronavirus disease 2019Effects of ageMonotherapyLogistic regressionCOVID-19 susceptibilityPrevalence
2021
Mental and neurological disorders and risk of COVID-19 susceptibility, illness severity and mortality: A systematic review, meta-analysis and call for action
Liu L, Ni S, Yan W, Lu Q, Zhao Y, Xu Y, Mei H, Shi L, Yuan K, Han Y, Deng J, Sun Y, Meng S, Jiang Z, Zeng N, Que J, Zheng Y, Yang B, Gong Y, Ravindran A, Kosten T, Wing Y, Tang X, Yuan J, Wu P, Shi J, Bao Y, Lu L. Mental and neurological disorders and risk of COVID-19 susceptibility, illness severity and mortality: A systematic review, meta-analysis and call for action. EClinicalMedicine 2021, 40: 101111. PMID: 34514362, PMCID: PMC8424080, DOI: 10.1016/j.eclinm.2021.101111.Peer-Reviewed Original ResearchMental disordersIllness severityOdds ratioRisk of COVID-19 susceptibilitySystematic reviewPre-existing schizophreniaCalculate pooled odds ratiosPre-existing dementiaPre-existing mood disorderMeta-analysisAttention-deficit hyperactivity disorderSubgroup analysisCross-sectional studyPooled odds ratioNeurological disordersCOVID-19 susceptibilityMood disordersRandom-effects modelAssociated with pre-existingWeb of ScienceAssociated with high mortalityMiddle-income regionsSignificantly higher riskYoung COVID-19 patientsMeta-regression analysisACE2 Netlas: In silico Functional Characterization and Drug-Gene Interactions of ACE2 Gene Network to Understand Its Potential Involvement in COVID-19 Susceptibility
Pathak GA, Wendt FR, Goswami A, Koller D, De Angelis F, Initiative C, Polimanti R. ACE2 Netlas: In silico Functional Characterization and Drug-Gene Interactions of ACE2 Gene Network to Understand Its Potential Involvement in COVID-19 Susceptibility. Frontiers In Genetics 2021, 12: 698033. PMID: 34512723, PMCID: PMC8429844, DOI: 10.3389/fgene.2021.698033.Peer-Reviewed Original ResearchGenome-wide association studiesGenetic variationFunctional characterizationCOVID-19 susceptibilityHuman genetic variationSilico functional characterizationDrug-gene interaction databaseTranscriptomic regulationGene networksGenetic variant associationsMetabolic domainsMulti-level characterizationPhenome-wide associationAssociation studiesDrug-gene interactionsVariant associationsInteraction databasesGenesKey adhesion moleculeGenetic variantsPhenotype categoriesPotential involvementMiRNAsAdhesion moleculesPotential mechanisms
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply